title: The case in favour of probiotics before, during and after pregnancy: insights from the first 1,500 days.
abstract: Successful human reproduction requires microbial homeostasis in the female reproductive tract, and colonisation of the newborn with beneficial microbes. In order to prevent several complications associated with dysbiosis, the administration of probiotics is more often being considered. The objective of the enclosed review was to examine the rationale for probiotic utility before and during pregnancy and in the early phase of infant life. The conclusions emerged from a panel of researchers who met during the International Scientific Association for Probiotics and Prebiotics (ISAPP) workshop held in Washington, DC, USA in 2015. The group concluded based upon the current literature, that a case can be made for the use of a specific sets of probiotic organisms during the first 1,500 days of life, with the goal of a healthy pregnancy to term, and a healthy start to life with lowered risk of infections and inflammatory events. The key to successfully translating these recommendations to practice is that products be made available and affordable to women in developed and developing countries.
authors.affiliation: 1 Centre for Human Microbiome and Probiotic Research, Lawson Health Research Institute, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada.|2 Department of Microbiology and Immunology, University of Western Ontario, London, Ontario N6A 5C1, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Reid
authors.affiliation: 3 Functional Foods Forum, University of Turku, Itäinenpitkäkatu 4 A, 20014 Turku, Finland.
authors.forename: H
authors.initials: H
authors.lastname: Kumar
authors.affiliation: 4 Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh, P.O. Box 128, Dhaka 1000, Bangladesh.
authors.forename: A I
authors.initials: AI
authors.lastname: Khan
authors.affiliation: 5 Department of Pediatrics, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, 20520 Turku, Finland.
authors.forename: S
authors.initials: S
authors.lastname: Rautava
authors.affiliation: 6 Melbourne Medical School Centre for Indigenous Health Equity, 207 Bouverie St, Parkville, Melbourne 3010, Victoria, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Tobin
authors.affiliation: 3 Functional Foods Forum, University of Turku, Itäinenpitkäkatu 4 A, 20014 Turku, Finland.
authors.forename: S
authors.initials: S
authors.lastname: Salminen
mesh_terms: D004219:District of Columbia; D064806:Dysbiosis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D000068104:Infant Health; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control*; D019936:Probiotics / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States
keywords: Bifidobacterium; C section; Lactobacillus; microbiota; probiotics